Development

Scott Ripley is the general manager, nucleic acid, for Cytiva.

Articles

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Accelerating the Development of mRNA Therapeutics

Grant Playter is the Assistant Editor for 

Scaling up chromatography resins requires a thorough understanding of their intended use.

Approaches to Scaling Up Chromatography Processes

Stéphane Varray, PhD, is senior director, head of Commercial Development, Microbial Business Unit, at Lonza.

Successful scale-up and BLA filings for products manufactured by microbial biomanufacturing require strategic planning.

Outlining Successful Steps for Scale-Up and BLA Filings

Feliza Mirasol is the science editor for 

The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.

Large-Scale Single-Use Bioreactors Can Maximize Long-Term Scale Up

Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.

Denali Therapeutics and Takeda to Jointly Develop and Commercialize Investigational Treatment for FTD-GRN

Jennifer Markarian is manufacturing editor of BioPharm International.

Mechanistic models provide process understanding for developing robust manufacturing processes and for scale up and tech transfer.

Using Digital Twins to Model Process Chromatography

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.